Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-04-11

FDA Approved: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE — Original Application (Solco Healthcare LLC)

View source ↗

Summary

FDA approved a generic fixed-dose combination of candesartan cilexetil and hydrochlorothiazide for hypertension under an Original Application.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Candesartan Cilexetil and Hydrochlorothiazide (Candesartan cilexetil and hydrochlorothiazide)

Snippet

ORIG AP for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE (CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE)